Search

Your search keyword '"Nikolaos Kanellias"' showing total 3 results
Start Over Author "Nikolaos Kanellias" Publisher ovid technologies (wolters kluwer health)
3 results on '"Nikolaos Kanellias"'

1. Prevalence of MGCS Among Patients With Monoclonal Gammopathies

Author

Foteini Theodorakakou, Despina Fotiou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vassiliki Spiliopoulou, Panagiotis Malandrakis, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Evangelos Terpos, Meletios A. Dimopoulos, and Efstathios Kastritis

Subjects
Hematology
Published
2023

2. B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Author

Evangelos Terpos, Nikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Efstathios Kastritis, Vassilis Koutoulidis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Panagiotis Malandrakis, Tina Bagratuni, Maria Roussou, Lia A Moulopoulos, and Meletios A Dimopoulos

Subjects
Hematology
Published
2022

3. Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Author

Efstathios Kastritis, Bruno Paiva, Ourania E. Tsitsilonis, Pantelis Rousakis, Magdalini Migkou, Evangelos Terpos, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Dimitrios C. Ziogas, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Alexandra Argyriou, Maria Gavriatopoulou, Ioannis Kostopoulos, Nikolaos Kanellias, Marilyn Spyropoulou-Vlachou, Ioannis P. Trougakos, and Aristea-Maria Papanota

Subjects
Oncology, medicine.medical_specialty, Suitable method, Next-generation flow (NGF), Tumor burden, Phenotypic profiles, Article, Flow cytometry, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, MRD Persistence, Minimal residual disease (MRD), Multiple myeloma, 030304 developmental biology, 0303 health sciences, medicine.diagnostic_test, lcsh:RC633-647.5, business.industry, Complete remission, lcsh:Diseases of the blood and blood-forming organs, Hematology, medicine.disease, Minimal residual disease, 3. Good health, body regions, medicine.anatomical_structure, 030220 oncology & carcinogenesis, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Bone marrow, business, Cytometry
Abstract

Supplemental Digital Content is available in the text, Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results